Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 16/20 | 0.69 |
| ▸ | NPC1 | O15118 | 14/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 14/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.69 |
| ▸ | HPGD | P15428 | 13/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.69 |
| ▸ | TP53 | P04637 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 9/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.66 |
| ▸ | RELA | Q04206 | 5/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | CASP3 | P42574 | 4/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131700 | 0.89 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2491813 | 0.88 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14668236 | 0.86 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14947173 | 0.84 | ALDH1A1 (0.96) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11646171 | 0.84 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31154077 | 0.83 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL474369 | 0.83 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2245161 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3288386 | 0.82 | ALDH1A1 (1.00) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15047797 | 0.82 | ALDH1A1 (0.93) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244728-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD (EE) | 2021-08-12 | — | — | US | disclosed |
| US-20200113895-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2020-04-16 | — | — | US | disclosed |
| US-20180036305-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2018-02-08 | — | — | US | disclosed |
| US-20180036305-A1 | Method of treating peripheral neuropathy | CHEMEDEST LTD. (EE) | 2018-02-08 | — | — | US | disclosed |
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | CHEMEDEST LTD. (EE) | 2016-05-19 | — | — | US | disclosed |
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | CHEMEDEST LTD. (EE) | 2016-05-19 | — | — | US | disclosed |
| EP-2509953-B1 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS | GENECODE AS (EE) | 2016-03-30 | — | — | EP | disclosed |
| US-8901129-B2 | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators | GENECODE AS (EE) | 2014-12-02 | — | — | US | disclosed |
| US-8901129-B2 | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators | GENECODE AS (EE) | 2014-12-02 | — | — | US | disclosed |
| WO-2014041179-A1 | TREATMENT OF PERIPHERAL NEUROPATHY USING GFR(ALPHA)3 TYPE RECEPTOR AGONISTS | CHEMEDEST LTD. (EE) | 2014-03-20 | — | — | WO | disclosed |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GENECODE AS (EE) | 2013-01-31 | — | — | US | disclosed |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GENECODE AS (EE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011070177-A2 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS | BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136159-A1 | Method for Treating Peripheral Neuropathy | GFRA3, GAP43, GFRA2 | RAB9A 2074/4885NPC1 1229/4885SMN1; SMN2 218/4885 |
| US-20210244728-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA2, GFRA1 | RAB9A 2798/4885NPC1 1166/4885SMN1; SMN2 294/4885 |
| US-20180036305-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA2, GAP43 | RAB9A 2424/4885NPC1 1178/4885SMN1; SMN2 205/4885 |
| US-20130030180-A1 | Methods of Facilitating Neural Cell Survival Using GDNF Family Ligand (GFL) Mimetics or RET Signaling Pathway Activators | GFRA2, GFRA1, GFRA3 | RAB9A 1055/4885NPC1 1674/4885SMN1; SMN2 18/4885 |
| US-20200113895-A1 | Method of treating peripheral neuropathy | GFRA3, GFRA1, GFRA2 | RAB9A 2528/4885NPC1 1022/4885SMN1; SMN2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.